HK1022919A1 - Chemically modified polypeptides - Google Patents

Chemically modified polypeptides

Info

Publication number
HK1022919A1
HK1022919A1 HK00101893A HK00101893A HK1022919A1 HK 1022919 A1 HK1022919 A1 HK 1022919A1 HK 00101893 A HK00101893 A HK 00101893A HK 00101893 A HK00101893 A HK 00101893A HK 1022919 A1 HK1022919 A1 HK 1022919A1
Authority
HK
Hong Kong
Prior art keywords
modified polypeptide
chemically modified
modified polypeptides
polypeptide
modified
Prior art date
Application number
HK00101893A
Other languages
English (en)
Inventor
Motoo Yamasaki
Toshiyuki Suzawa
Ken Kobayashi
Noboru Konishi
Shiro Akinaga
Kumiko Maruyama
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of HK1022919A1 publication Critical patent/HK1022919A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK00101893A 1997-06-06 2000-03-28 Chemically modified polypeptides HK1022919A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14934297 1997-06-06
PCT/JP1998/002504 WO1998055500A1 (fr) 1997-06-06 1998-06-05 Polypeptides chimiquement modifies

Publications (1)

Publication Number Publication Date
HK1022919A1 true HK1022919A1 (en) 2000-11-03

Family

ID=15473025

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101893A HK1022919A1 (en) 1997-06-06 2000-03-28 Chemically modified polypeptides

Country Status (15)

Country Link
US (2) US6583267B2 (ja)
EP (1) EP0921131B1 (ja)
JP (1) JP4011124B2 (ja)
KR (1) KR100565022B1 (ja)
CN (1) CN1250566C (ja)
AT (1) ATE469166T1 (ja)
AU (1) AU744085B2 (ja)
CA (1) CA2263795C (ja)
DE (1) DE69841682D1 (ja)
HK (1) HK1022919A1 (ja)
HU (1) HUP0001153A3 (ja)
NO (1) NO322978B1 (ja)
NZ (1) NZ334068A (ja)
RO (1) RO121474B1 (ja)
WO (1) WO1998055500A1 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
NZ334068A (en) * 1997-06-06 2000-07-28 Kyowa Hakko Kogyo Kk Polypeptides chemically modified with polyalkylene glycol derivatives
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
EP1517710B1 (en) 2002-06-21 2011-03-30 Novo Nordisk Health Care AG Pegylated factor vii glycoforms
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
MX2007007580A (es) 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
CN104593348A (zh) 2006-05-24 2015-05-06 诺沃—诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CA2662753C (en) 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
ES2476915T3 (es) 2007-08-27 2014-07-15 Ratiopharm Gmbh Formulación líquida de conjugado de G-CSF
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
AU2010341516B2 (en) 2009-12-21 2014-01-16 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
BR112014000055A2 (pt) 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
SI3584255T1 (sl) 2012-08-31 2022-05-31 Sutro Biopharma, Inc Modificirane aminokisline, ki vsebujejo azido skupino
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3111576A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (en) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
JPH0644927B2 (ja) * 1987-03-14 1994-06-15 日本油脂株式会社 徐放性活性成分放出剤
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH0796558B2 (ja) 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JP2931622B2 (ja) * 1989-05-27 1999-08-09 住友製薬株式会社 ポリエチレングリコール誘導体を得る製造方法
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
JPH03236400A (ja) * 1990-02-09 1991-10-22 Kirin Brewery Co Ltd 化学修飾ポリペプチド及びその用途
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JPH06319537A (ja) 1993-05-18 1994-11-22 Daikin Ind Ltd 修飾ペプチドおよびその製造方法
JP4011106B2 (ja) 1994-02-23 2007-11-21 協和醗酵工業株式会社 血小板増殖促進剤
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6884419B1 (en) 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
NZ334068A (en) 1997-06-06 2000-07-28 Kyowa Hakko Kogyo Kk Polypeptides chemically modified with polyalkylene glycol derivatives
DE69925830T2 (de) * 1998-04-28 2006-05-04 Applied Research Systems Ars Holding N.V. Peg-lhrh analog konjugate

Also Published As

Publication number Publication date
KR20000068069A (ko) 2000-11-25
AU744085B2 (en) 2002-02-14
EP0921131A1 (en) 1999-06-09
NO322978B1 (no) 2006-12-18
AU7551298A (en) 1998-12-21
JP4011124B2 (ja) 2007-11-21
US20020028912A1 (en) 2002-03-07
US20030195339A1 (en) 2003-10-16
CA2263795A1 (en) 1998-12-10
ATE469166T1 (de) 2010-06-15
EP0921131B1 (en) 2010-05-26
CN1250566C (zh) 2006-04-12
RO121474B1 (ro) 2007-06-29
NO990560D0 (no) 1999-02-05
DE69841682D1 (de) 2010-07-08
HUP0001153A3 (en) 2000-12-28
US6583267B2 (en) 2003-06-24
EP0921131A4 (en) 2002-11-27
CA2263795C (en) 2008-02-19
US7547675B2 (en) 2009-06-16
CN1236370A (zh) 1999-11-24
NO990560L (no) 1999-03-26
HUP0001153A2 (hu) 2000-10-28
NZ334068A (en) 2000-07-28
WO1998055500A1 (fr) 1998-12-10
KR100565022B1 (ko) 2006-03-30

Similar Documents

Publication Publication Date Title
HK1022919A1 (en) Chemically modified polypeptides
HUT54303A (en) Process for producing medicaments comprising cytokin, suitable for systemic treatment of preneoplastic lesions
IL96549A0 (en) Production of a biologically active protein
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
EE04967B1 (et) Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
ATE84048T1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
HUP0001138A3 (en) Amino acids containing benzodioxane or benzoxazine, pharmaceutical compositions thereof and process for producing the same
HUT59833A (en) Process for producing pharmaceutical compositions containing calcitoninogene like peptides for treating erectional disfunctions
AU579887B2 (en) Concrete admixture
CZ63895A3 (en) 5-vinyl-quinolone-carboxylic, 5-vinyl-naphthyridon-carboxylic, +5-ethinyl-quinolone-carboxylic and 5-ethinyl-naphthyridon-carboxylic acids, process of their preparation, medicaments in which said compounds are comprised and their use
HUT62031A (en) Process for producing recombinant aprotinin derivatives and pharmaceutical compositions comprising same
DE237398T1 (de) Verfahren zur herstellung biologisch aktiver polypeptide, so erhaltene polypeptide und diese enthaltende zusammensetzungen.
HUT57708A (en) Process for producing non ionic carboxamide derivative contrast materials
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
EP0783003A4 (en) NEW POLYPEPTIDES
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ATA234689A (de) Neue 2-carbonyl substituierte n,n'-di(trimethoxybenzoyl)piperazine, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
EP0723016A3 (en) Leukocyte activation factor
CA2247998A1 (en) Fragments of cr1 and their use
CA2087450A1 (en) Stable and bioactive modified somatotropins
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
AU6446190A (en) Process for inducing analgesia, peptides and therapeutic compositions
CA2153071A1 (en) Derivatized calcitonins
AU6347290A (en) Polypeptide, production thereof, and pharmaceutical composition and cosmetic containing said polypeptide
AU708825C (en) Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110605